BioInfra Life Science Inc. (XKON:266470)
South Korea
· Delayed Price · Currency is KRW 280.00
+15.00 (5.66%)
At close: Dec 5, 2025
BioInfra Life Science Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|
Period Ending | Mar '20 Mar 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 |
| Operating Revenue | 1,779 | 1,875 | 1,551 | 1,370 | 1,550 |
| Other Revenue | -0 | - | - | - | 0 |
| Revenue | 1,779 | 1,875 | 1,551 | 1,370 | 1,550 |
| Revenue Growth (YoY) | 27.54% | 20.82% | 13.25% | -11.60% | - |
| Cost of Revenue | 953.44 | 978.91 | 723.68 | 622.76 | 662.63 |
| Gross Profit | 825.48 | 895.63 | 827.76 | 747.16 | 887.05 |
| Selling, General & Admin | 2,916 | 2,944 | 2,992 | 2,721 | 3,381 |
| Research & Development | 1,123 | 1,115 | 1,162 | 975.6 | 941.9 |
| Amortization of Goodwill & Intangibles | 113.15 | 111.58 | 107.15 | 81.58 | 24.85 |
| Other Operating Expenses | 23.15 | 21.81 | 22.09 | 20.5 | 22.44 |
| Operating Expenses | 4,379 | 4,265 | 4,442 | 3,866 | 4,413 |
| Operating Income | -3,554 | -3,369 | -3,614 | -3,119 | -3,526 |
| Interest Expense | -295.64 | -205.65 | -27.2 | -60.16 | -55.3 |
| Interest & Investment Income | 161.63 | 140.74 | 125.19 | 76.52 | 145.21 |
| Currency Exchange Gain (Loss) | 1.53 | -2.38 | 11.7 | -37.42 | 43.17 |
| Other Non Operating Income (Expenses) | 76.79 | 80.69 | -343.42 | 72.88 | 19.79 |
| EBT Excluding Unusual Items | -3,610 | -3,356 | -3,848 | -3,067 | -3,373 |
| Gain (Loss) on Sale of Investments | 15.49 | 77.2 | 76.07 | - | - |
| Gain (Loss) on Sale of Assets | - | - | -35.41 | -112.69 | -55.59 |
| Asset Writedown | - | - | - | -816.23 | -1,175 |
| Pretax Income | -3,594 | -3,278 | -3,807 | -3,996 | -4,603 |
| Net Income | -3,594 | -3,278 | -3,807 | -3,996 | -4,603 |
| Net Income to Common | -3,594 | -3,278 | -3,807 | -3,996 | -4,603 |
| Shares Outstanding (Basic) | 13 | 13 | 14 | 13 | 13 |
| Shares Outstanding (Diluted) | 13 | 13 | 14 | 13 | 13 |
| Shares Change (YoY) | -2.59% | -1.87% | 6.28% | 1.42% | - |
| EPS (Basic) | -266.28 | -243.11 | -277.01 | -309.00 | -361.00 |
| EPS (Diluted) | -266.28 | -243.11 | -277.01 | -309.00 | -361.00 |
| Free Cash Flow | -2,955 | -2,989 | -4,112 | -3,607 | -3,760 |
| Free Cash Flow Per Share | -218.93 | -221.65 | -299.20 | -278.95 | -294.93 |
| Gross Margin | 46.40% | 47.78% | 53.35% | 54.54% | 57.24% |
| Operating Margin | -199.77% | -179.72% | -232.93% | -227.65% | -227.50% |
| Profit Margin | -202.03% | -174.89% | -245.38% | -291.67% | -297.02% |
| Free Cash Flow Margin | -166.11% | -159.45% | -265.03% | -263.31% | -242.66% |
| EBITDA | -3,178 | -3,022 | -3,341 | -2,940 | -3,398 |
| EBITDA Margin | -178.62% | -161.21% | -215.33% | -214.63% | -219.25% |
| D&A For EBITDA | 376.3 | 347.07 | 273.1 | 178.4 | 127.89 |
| EBIT | -3,554 | -3,369 | -3,614 | -3,119 | -3,526 |
| EBIT Margin | -199.77% | -179.72% | -232.93% | -227.65% | -227.50% |
| Advertising Expenses | - | 62.51 | 47.7 | 47.05 | 53.05 |
Source: S&P Capital IQ. Standard template. Financial Sources.